Clinical Trial: Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer

U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07645118) titled 'Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer' on June 02.

Brief Summary: This is a small Phase II study testing whether targeted internal radiation treatment (HDREBT) followed by two doses of the immunotherapy drug Nivolumab is safe, practical, and potentially effective before patients undergo surgery (TME) to remove rectal cancer.

Study Start Date: July, 2026

Study Type: INTERVENTIONAL

Condition: Locally Advanced Rectal Cancer

Intervention: DRUG: Nivolumab

2 doses of nivolumab 3 mg/kg mg IV every 2 weeks

DEVICE: HDRBET

26 Gy in 4 fractions Administered over Days 1-4 as per institutional standard

P...